Clinical Trial Update: Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safinamide as add-on therapy for early idiopathic Parkinson's disease in patients on a stable dose of a single dopamine agonist.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• Xadago (safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED